Peter G. Schulam, MD, PhD, is chair of urology for Yale School of Medicine. As a clinician, he is nationally recognized for his expertise in minimally invasive surgery. His approach involves listening to and engaging with each new patient while providing a state-of-the-art diagnosis and an individualized treatment plan. “We want every patient to receive innovative, state-of-the-art care, but just as important, we want our physicians, nurses and staff to treat every patient with compassion and kindness,” he says.
After becoming chair in 2012, Dr. Schulam built a multidisciplinary team in urologic oncology for Yale Medicine. Under his direction, one of the fundamental missions has been to further improve and refine prostate cancer detection. As clinical program leader of the prostate and urological cancers program, he established a program for MRI-fusion guided biopsy. Dr. Schulam is a leading proponent of MRI imaging and targeted biopsy. He believes that accurate diagnosis in men with prostate cancer allows for an improved ability to determine who should be treated, and which men can avoid surgery and be followed by active surveillance.
In addition to his focus on patient care, Dr. Schulam is cofounder of the Yale University Center for Biomedical and Interventional Technology (CBIT), an interdisciplinary initiative to foster greater innovation in medical technology by catalyzing medical device innovation, improving clinical efficiency and efficacy and lowering healthcare costs.
Dr. Schulam has been recognized as one of the Top Doctors in the state by Castle Connolly Medical Ltd. He is a professor of urology at Yale School of Medicine.
Smilow Cancer Hospital, Yale Medicine